88P Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)

التفاصيل البيبلوغرافية
العنوان:	88P Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
المؤلفون:	Persano, M., Rimini, M., Tada, T., Suda, G., Shimose, S., Kudo, M., Yoo, C., Cheon, J., Finkelmeier, F., Lim, H.Y., Presa, J., Masi, G., Bergamo, F., Iavarone, M.A., Cabibbo, G., Foschi, F.G., Piscaglia, F., Cascinu, S., Scartozzi, M., Gardini, A. Casadei
المصدر:	In Immuno-Oncology and Technology December 2023 20 Supplement
قاعدة البيانات:	ScienceDirect

الوصف
تدمد:	25900188
DOI:	10.1016/j.iotech.2023.100560